For a better experience, click the Compatibility Mode icon above to turn off Compatibility Mode, which is only for viewing older websites.

Translational Immunoengineering Biosensors for Personalized Disease Theranostics at Point-of-Care

Tuesday, October 31, 2017

1:30 PM-3:00 PM

BIOMED Special Seminar

Translational Immunoengineering Biosensors for Personalized Disease Theranostics at Point-of-Care

Umer Hassan, PhD
Research Scientist
Department of Bioengineering
University of Illinois at Urbana-Champaign (UIUC)
Research Affiliate
Biomedical Research Center
Mills Breast Cancer Institute
Carle Foundation Hospital

Infectious diseases remain the leading cause of mortality around the world. Diagnosing disease at its onset will have a critical impact in timely administrating the therapeutic interventions that could result in saving patient lives. The availability of Point-of-Care (PoC) diagnostic testing can have a significant impact on the early patient stratification. In this talk, I will discuss my research work on development of PoC biosensors for disease diagnostics in particular HIV/AIDS and sepsis. I will present the differential immuno-capture technology that I developed for specific leukocyte counting and quantifying the cell surface antigen expression levels.

First, roughly 33 million people are infected with HIV with 69% of them living in sub-Saharan Africa. I will present the microfluidic biochip developed to electrically enumerate CD4+ and CD8+ T cells for AIDS diagnostics from a drop of blood. In clinical studies, biochip is tested from blood samples collected from healthy and HIV infected donors. Second, in case of sepsis, roughly 5 million patients are admitted annually to ICUs in the United States, of these, severe sepsis strikes to more than 1 million people, with an estimated 30 percent of these people die. My work has been focused on quantifying CD64 neutrophil, total leukocyte count and its subtypes as potential cellular biomarkers for sepsis stratification. I have developed a biochip that can quantify these biomarkers using only 10μL of whole blood at PoC in less than 20 minutes and validated it in extensive clinical studies. Further, I will discuss the integration of these biosensors in the predictive data analytical systems for individualized patient stratification.

I will conclude with the discussion on the emerging challenges in infectious disease diagnostics and therapeutics in particular the roles of immuno-engineering, antibiotic resistance and precision pharmacotherapy in patients’ stratification. PoC personalized-theranostics for infectious diseases could
 drastically reduce the time to 
appropriate treatment, dramatically increase survival rates, and save healthcare systems billions of dollars around the world. Theranostics enabled by advances in microfluidics and nanotechnologies can be an important part of the solution.

Umer Hassan, PhD, is a Research Scientist in the Department of Bioengineering at University of Illinois Urbana-Champaign (UIUC) with a Research Affiliate appointment at Carle Foundation Hospital, Urbana. Dr. Hassan completed Masters and Doctoral studies from UIUC in 2015. His research has been focused on developing point-of-care (PoC) translational biosensors for infectious disease diagnostic and therapeutic applications.

Dr. Hassan has received Brandt Early Career Investigator Award in Precision Medicine (2017), BMES Career Development Award (2017), Baxter Young Investigator Award (2016, 17), Emerging Engineer Award (2015), Cozad New Venture Competition Award (2014), NSF I-Corps Fellowship (2014) and Our Common Future Fellowship (2010). In 2014, Dr. Hassan cofounded a startup, Prenosis, Inc. that is working on commercializing his developed biosensors.

Contact Information

Ken Barbee

Remind me about this event. Notify me if this event changes. Add this event to my personal calendar.


Bossone Research Center, Room 709, located at 32nd and Market Streets.


  • Undergraduate Students
  • Graduate Students
  • Faculty
  • Staff